1. Home
  2. FBK vs BEAM Comparison

FBK vs BEAM Comparison

Compare FBK & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FBK
  • BEAM
  • Stock Information
  • Founded
  • FBK 1906
  • BEAM 2017
  • Country
  • FBK United States
  • BEAM United States
  • Employees
  • FBK N/A
  • BEAM N/A
  • Industry
  • FBK Major Banks
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FBK Finance
  • BEAM Health Care
  • Exchange
  • FBK Nasdaq
  • BEAM Nasdaq
  • Market Cap
  • FBK 2.0B
  • BEAM 1.8B
  • IPO Year
  • FBK 2016
  • BEAM 2020
  • Fundamental
  • Price
  • FBK $40.61
  • BEAM $17.00
  • Analyst Decision
  • FBK Hold
  • BEAM Strong Buy
  • Analyst Count
  • FBK 5
  • BEAM 11
  • Target Price
  • FBK $54.00
  • BEAM $50.50
  • AVG Volume (30 Days)
  • FBK 321.8K
  • BEAM 3.0M
  • Earning Date
  • FBK 04-14-2025
  • BEAM 05-06-2025
  • Dividend Yield
  • FBK 1.87%
  • BEAM N/A
  • EPS Growth
  • FBK 14.69
  • BEAM N/A
  • EPS
  • FBK 2.73
  • BEAM N/A
  • Revenue
  • FBK $465,280,000.00
  • BEAM $63,518,000.00
  • Revenue This Year
  • FBK $37.87
  • BEAM N/A
  • Revenue Next Year
  • FBK $19.11
  • BEAM $6.32
  • P/E Ratio
  • FBK $14.88
  • BEAM N/A
  • Revenue Growth
  • FBK 2.18
  • BEAM N/A
  • 52 Week Low
  • FBK $33.35
  • BEAM $13.53
  • 52 Week High
  • FBK $58.88
  • BEAM $35.25
  • Technical
  • Relative Strength Index (RSI)
  • FBK 35.58
  • BEAM 40.71
  • Support Level
  • FBK $39.47
  • BEAM $16.04
  • Resistance Level
  • FBK $43.90
  • BEAM $17.94
  • Average True Range (ATR)
  • FBK 2.11
  • BEAM 1.84
  • MACD
  • FBK -0.15
  • BEAM 0.26
  • Stochastic Oscillator
  • FBK 21.84
  • BEAM 44.24

About FBK FB Financial Corporation

FB Financial Corp is a bank holding company. The company through its wholly-owned bank subsidiary provides commercial and consumer banking services to clients in select markets in Tennessee, North Alabama, and North Georgia. The company segment includes Banking and Mortgage. It generates revenue from the Banking segment which provides a full range of deposit and lending products and services to corporate, commercial, and consumer customers. The Mortgage segment includes the servicing of residential mortgage loans and the packaging and securitization of loans to governmental agencies.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: